In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
BUSINESS
Takeda Shareholders Block Old Guard Group’s Claw-Back Pitch
Shareholders of Takeda Pharmaceutical on June 27 voted down a proposal calling for the addition of a “claw-back clause” to the company’s articles of incorporation, which would oblige its board members to return their pay when excessive investments result in…
To read the full story
Related Article
- Takeda’s CEO Pay Tops 2 Billion Yen in FY2019; Old Guard Pitch to Send in External Director Rejected
June 25, 2020
- Takeda Introduces Claw-Back Policy for Executives Liable for Business Loss, Misconducts
April 2, 2020
- Claw-Back Clause Thwarted, but Majority of Takeda Shareholders Voted in Favor
July 4, 2019
- Takeda to Propose Adding Shire Integration as Performance Objective for Execs’ Stock Compensation
June 14, 2019
- Takeda Founding Family Member Presses for Claw-Back Clause
June 13, 2019
- Takeda Shareholders Pitch Claw-Back Clause, Urge Execs to Return Pay If Loss Incurred on Big Investment
May 31, 2019
BUSINESS
- Nippon Shinyaku’s Viltepso Patents Invalid: US Jury Verdict
December 24, 2024
- Increased Off-Year Pressure on LLPs Would Only Exacerbate Supply Crunch: Industry Officials
December 24, 2024
- Eisai/Fujirebio Tie Up in Biomarker Research for Neurodegenerative Diseases
December 24, 2024
- Orion Now MA Holder of Parkinson’s Meds Stalevo, Comtan in Japan
December 24, 2024
- Shionogi to Take Full Control of 2 China Joint Ventures
December 24, 2024
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…